INVESTOR RESOURCES

iCHOR COMPANY INFORMATION, NEWS & PRESENTATIONS

Corporate Overview

iCHOR was founded by Interventional Radiologist Dr. Troy Long and industry veteran Tim Blair who saw an opportunity to develop new technologies to address the large unmet needs in treating peripheral vascular occlusions.  They have devised a technology that has converted the tried and proven Fogarty balloon sweep method from an open surgery to a minimally-invasive endovascular procedure.

The overall corporate objective is to focus on creating a one-size-fits-all system that replicates successful parameters of surgical clot removal while addressing the shortcomings of current therapeutic options. The Team’s long-term vision is for the iSWEEP system to become the standard of care and first-line therapy for treating peripheral vascular occlusions, increasing clinical flexibility while delivering improved outcomes at a lower cost.

The iCHOR team consists of a group of experienced multi-disciplinary members, including entrepreneurs, executives, physicians, regulatory experts, and engineers. Together, we bring a broad range of experience in the development, regulatory approval, and commercialization of medical devices in the peripheral vascular space.

Quick Resources

PITCH DECKS

NAMSA CASE STUDY

iCHOR at LSI '24

Medline Review Articles

The Latest News

Real-World Limited Market Release Evidence iCHOR 14F iDVT Venous Reperfusion System

The iCHOR iDVT venous reperfusion system has demonstrated consistent safety, efficacy, and procedural performance across a diverse spectrum of clinical presentations in limited market release evaluation accessing patients in both Hospital and Ambulatory settings. Clinical Evidence at a Glance In 77 documented procedures performed by 20 physicians, the iDVT platform achieved: 95% technical success rate and 93.5% procedural success rate…

iCHOR Funding Early Commercialization

iCHOR Vascular. Clearing the path As iCHOR Vascular finishes the limited market release (LMR) data and evaluation, we are transitioning into a planned early commercial funding round aimed at targeted revenue milestones combined with real-world clinical data across 3 FDA cleared devices uniquely designed to treat peripheral vascular occlusions across arteries, veins, and dialysis access. Series A investors will anchor…

Investor Relations

Contact Us

    P.O. Box 810787 Boca Raton, FL 33481

    + 1 954-483-4525

    info@ichorvascular.com